Literature DB >> 30503326

Dolutegravir in sub-Saharan Africa: context is crucial.

Jienchi Dorward1, Raph L Hamers2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30503326     DOI: 10.1016/S2352-3018(18)30331-X

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


× No keyword cloud information.
  3 in total

1.  Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV.

Authors:  Ryan P Coyle; Mary Morrow; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson; Jose R Castillo-Mancilla
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

2.  Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda.

Authors:  Leah Mbabazi; Mariah Sarah Nabaggala; Suzanne Kiwanuka; Juliet Kiguli; Eva Laker; Arthur Kiconco; Stephen Okoboi; Mohammed Lamorde; Barbara Castelnuovo
Journal:  BMC Womens Health       Date:  2022-06-27       Impact factor: 2.742

3.  Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study.

Authors:  Henry Zakumumpa; Freddy Eric Kitutu; Helen Byomire Ndagije; Nakitto-Kesi Diana; Jacquellyn Nambi Ssanyu; Ronald Kiguba
Journal:  BMC Infect Dis       Date:  2021-12-07       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.